Cytosorbents Corp (CTSO) CFO Buys $19,470.00 in Stock

Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch acquired 3,000 shares of the stock in a transaction on Friday, May 10th. The shares were bought at an average cost of $6.49 per share, for a total transaction of $19,470.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Shares of NASDAQ:CTSO traded up $0.04 on Thursday, hitting $6.90. 900 shares of the company’s stock were exchanged, compared to its average volume of 147,309. The stock has a market cap of $223.88 million, a P/E ratio of -12.40 and a beta of 1.52. Cytosorbents Corp has a 1-year low of $6.35 and a 1-year high of $14.95. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.52 and a current ratio of 3.70.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. The business had revenue of $5.19 million during the quarter, compared to analysts’ expectations of $6.03 million. Cytosorbents had a negative return on equity of 103.90% and a negative net margin of 83.93%. On average, equities research analysts predict that Cytosorbents Corp will post -0.56 EPS for the current year.

CTSO has been the topic of a number of research analyst reports. Maxim Group restated a “buy” rating and issued a $18.00 target price on shares of Cytosorbents in a research report on Friday, March 8th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Cytosorbents in a research report on Friday, March 8th. Finally, ValuEngine upgraded Cytosorbents from a “hold” rating to a “buy” rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $14.67.

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new position in shares of Cytosorbents during the 1st quarter worth about $47,000. Stephens Inc. AR acquired a new position in shares of Cytosorbents during the 4th quarter worth about $81,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Cytosorbents by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,442 shares of the medical research company’s stock valued at $84,000 after purchasing an additional 8,155 shares during the period. Virtu Financial LLC acquired a new stake in shares of Cytosorbents in the 4th quarter valued at about $92,000. Finally, Menta Capital LLC acquired a new stake in shares of Cytosorbents in the 4th quarter valued at about $103,000. 27.19% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2019/05/16/cytosorbents-corp-ctso-cfo-buys-19470-00-in-stock.html.

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Further Reading: Capital gains and your 401(k) or IRA

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit